NEW YORK (TheStreet) -- CHANGE IN RATINGS
Apple was upgraded at Societe Generale to buy. $575 price target. Company is seeing higher demand, and Android demand could be weakening, Societe Generale said.
Archer-Daniels-Midland was upgraded at Bank of America/Merrill Lynch to buy from underperform. New analyst has a $44 price target. Company should benefit from large grain and oilseed crops, BofA/Merrill said.
Bunge was upgraded at BofA/Merrill to buy from neutral. New analyst has a $90 price target. Company should benefit from large crops in Brazil and the U.S., BofA/Merrill said.
Companhia Brasileira De Distribuicao was upgrade to buy at TheStreet Ratings.
Capital Bank was downgraded at Compass Point to neutral from buy. Valuation call, based on a $24 price target, Compass Point said.
Chipotle was downgraded at Miller Tabak to hold from buy. Valuation call, based on a fair value of $490 a share, Miller Tabak said.
Dean Foods was upgraded at BMO Capital to outperform. $23 price target. Adverse operating conditions will likely peak shortly, BMO Capital said.
First Horizon was downgraded at RBC Capital to sector perform from outperform. $11 price target. Company is facing a more challenging fundamental outlook, RBC Capital said.
Stryker was downgraded to hold at TheStreet Ratings.
General Mills was downgraded at BofA/Merrill to neutral from buy. $51 price target. Company is facing lower sales, BofA/Merrill said.
Goodyear was downgraded to hold from buy at Deutsche Bank. $26 price target. Industry has ramped up capital spending, Deutsche Bank said.
Kellogg was downgraded at BofA/Merrill to underperform from buy. $62 price target. Estimates also lowered, given reduced sales expectations, BofA/Merrill said.
Kaiser Aluminum was downgraded at Keybanc to hold from buy. Company could be hurt by weaker aerospace plate pricing, Keybanc said.
Kaiser Aluminum was downgraded at Sterne Agee to neutral. Company is facing pricing pressure and lacks near-term catalysts, Sterne Agee said.
Myriad Genetics downgraded at Credit Suisse to underperform from neutral. $20 price target. Company is facing increased competition, Credit Suisse said.
Parker Hannifin was upgraded at Robert Baird to outperform from neutral. $122 price target. Company is making progress on the cost side and is seeing better distributor demand, Robert Baird said.
Revlon was downgraded at BMO Capital to market perform. Valuation call, based on a $31 price target, BMO Capital said.
Stock Comments / EPS Changes
Albemarle estimates were lifted at Jefferies. Numbers were increased into 2014. Driven by Catalysts and Fine Chemistry segment with opportunity to flex the balance sheet, Jefferies said. Buy rating.
Ingersoll-Rand estimates and price target were lifted at UBS. Company should benefit from multiyear nonresidential construction recovery, UBS said. $74 price target and buy rating.
Baker Hughes estimates, price target were raised at Jefferies. BHI boosted its estimates into 2014, Jefferies said. Progress in international expansion, Jefferies also said. $65 price target and buy rating.
Baker Hughes numbers were boosted at Credit Suisse. Shares are now seen reaching $64. Company is seeing better domestic margins, Credit Suisse said. Outperform rating.
Cytec estimates were lowered at Jefferies. Headwinds in aerospace composites, mining chemicals and phosphine, Jefferies said. $82 price target and hold rating
Goodrich Petroleum numbers were cut at Canaccord Genuity. Shares are now seen reaching $30. Estimates were also reduced, given the dilution from the recent equity offering, Canaccord Genuity said. Buy rating.
Honeywell International estimates, price target were increased at UBS. Estimates were raised across the board. Balanced portfolio expected to drive accelerating growth, with stable U.S. and Europe and improving trends in China, UBS said. $85 price target and neutral rating.
Imax estimates, price target were increased at Benchmark. Estimates were raised through 2014, Benchmark said. Expect the company to exceed earnings expectations this week, Benchmark said. Hold rating and new $29.45 price target.
Las Vegas Sands numbers were raised at Sterne Agee. Shares are now seen reaching $81. Company should continue to post solid growth in Macau and Singapore, Sterne Agee said.
Realogy estimates, price target were lowered at Credit Suisse. Shares now seen reaching $42. Estimates were also cut, given reduced average home sale prices, Credit Suisse said. Neutral rating.
Schlumberger estimates, price target were raised at Jefferies. Schlumberger boosted its numbers into 2014, Jefferies said. The company should benefit from its exposure to key emerging markets, Jefferies also said. $110 price target and buy rating.
Schlumberger estimates, price target were increased at Credit Suisse. Estimates were boosted through 2014. Company has a lot of operating momentum, Credit Suisse said. Neutral rating and new $105 price target.
>To submit a news tip, email: firstname.lastname@example.org.
Follow TheStreet on Twitter and become a fan on Facebook.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.
- Investment & Company Information
- Credit Suisse